+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drugs in Development, 2021

  • ID: 5331237
  • Drug Pipelines
  • March 2021
  • Region: Global
  • Global Markets Direct

FEATURED COMPANIES

  • Amgen Inc
  • CardioCreate Inc
  • Incyte Corp
  • Novartis AG
  • Sanofi
  • SARomics Biostructures AB
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels. It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Respiratory which include indications Hematological Tumor, Prostate Cancer, Solid Tumor, Diffuse Large B-Cell Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Peanut Allergy, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Triple-Negative Breast Cancer (TNBC).

The latest report SerineThreonine Protein Kinase Pim 1 - Drugs in Development, 2021, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • CardioCreate Inc
  • Incyte Corp
  • Novartis AG
  • Sanofi
  • SARomics Biostructures AB
  • MORE
Introduction
  • Report Coverage
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Overview

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • CardioCreate Inc
  • Guangzhou DM Intelligence Ltd
  • Incyte Corp
  • Inflection Biosciences Ltd
  • NewBay Medical Technology Co Ltd
  • Novartis AG
  • Sanofi
  • SARomics Biostructures AB
  • Shengke Pharmaceuticals (Jiangsu) Ltd
  • Sumitomo Dainippon Pharma Oncology, Inc
  • Vortex Biotechnology Corp
  • Yakult Honsha Co Ltd
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drug Profiles

Drugs to Inhibit PIM1 Kinase for Asthma and Peanut Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ETH-155008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
GDC-0570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Gene Therapy to Activate PIM1 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
IBL-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
INCB-53914 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LGB-321 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SBX-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit CSNK2 and PIM1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit PIM1 and PIM2 for Hematological Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit PIM1 for Solid Tumor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit Pim-1 for Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit PIM1 and PIM3 for Hematological Cancers - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SMI-4a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
TP-3654 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Dormant Products
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Discontinued Products
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Product Development Milestones
  • Featured News & Press Releases
  • May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020
  • Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis
  • May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors
  • Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer
  • Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology
  • Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Amgen Inc, 2021
  • Pipeline by CardioCreate Inc, 2021
  • Pipeline by Guangzhou DM Intelligence Ltd, 2021
  • Pipeline by Incyte Corp, 2021
  • Pipeline by Inflection Biosciences Ltd, 2021
  • Pipeline by NewBay Medical Technology Co Ltd, 2021
  • Pipeline by Novartis AG, 2021
  • Pipeline by Sanofi, 2021
  • Pipeline by SARomics Biostructures AB, 2021
  • Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2021
  • Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2021
  • Pipeline by Vortex Biotechnology Corp, 2021
  • Pipeline by Yakult Honsha Co Ltd, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Amgen Inc
  • CardioCreate Inc
  • Guangzhou DM Intelligence Ltd
  • Incyte Corp
  • Inflection Biosciences Ltd
  • NewBay Medical Technology Co Ltd
  • Novartis AG
  • Sanofi
  • SARomics Biostructures AB
  • Shengke Pharmaceuticals (Jiangsu) Ltd
  • Sumitomo Dainippon Pharma Oncology, Inc
  • Vortex Biotechnology Corp
  • Yakult Honsha Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll